Literature DB >> 16773502

Further clinical and genetic characterization of SPG11: hereditary spastic paraplegia with thin corpus callosum.

A Olmez1, G Uyanik, R K Ozgül, C Gross, S Cirak, B Elibol, B Anlar, B Winner, U Hehr, H Topaloglu, J Winkler.   

Abstract

Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative disorders leading to progressive spasticity of the lower limbs. Clinically, HSPs are divided into "pure" and "complicated" forms. In pure HSP, the spasticity of the lower limbs is the sole symptom, whereas in complicated forms additional neurological and non-neurological features are observed. Genetically, HSPs are divided into autosomal dominant (AD), autosomal recessive (AR) and X-linked (XL) forms. Up to date, 30 different HSPs are linked to different chromosomal loci and 11 genes could be defined for AR-HSP, AD-HSP and XL-HSP. SPG11, an AR-HSP (synonym: HSP11), is a complicated HSP associated with a slowly progressive spastic paraparesis, mental impairment and the development of a thin corpus callosum (TCC) during the course of the disease. SPG11 has been previously linked to chromosomal region 15q13 - 15. First, we applied rigid diagnostic criteria to systematically examine 20 Turkish families with autosomal recessive HSP for characteristic features of SPG11. We detected four large Turkish families with AR-HSP and TCC consistent with SPG11. Subsequent genetic linkage analysis of those 4 families refines the SPG11 locus further down to a small region of 2.93 cM with a maximum lod score of 11.84 at marker D15S659 and will guide further candidate gene analysis.

Entities:  

Mesh:

Year:  2006        PMID: 16773502     DOI: 10.1055/s-2006-923982

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

Review 1.  Recent advances in the genetics of spastic paraplegias.

Authors:  Giovanni Stevanin; Merle Ruberg; Alexis Brice
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

2.  SPG11: a consistent clinical phenotype in a family with homozygous spatacsin truncating mutation.

Authors:  Roberto Del Bo; Alessio Di Fonzo; Serena Ghezzi; Federica Locatelli; Giovanni Stevanin; Antonella Costa; Stefania Corti; Nereo Bresolin; Giacomo Pietro Comi
Journal:  Neurogenetics       Date:  2007-08-24       Impact factor: 2.660

3.  Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish.

Authors:  Laura Southgate; Dimitra Dafou; Jacqueline Hoyle; Nan Li; Esther Kinning; Peter Critchley; Andrea H Németh; Kevin Talbot; Parayil S Bindu; Sanjib Sinha; Arun B Taly; Seetharam Raghavendra; Ferenc Müller; Eamonn R Maher; Richard C Trembath
Journal:  Neurogenetics       Date:  2010-10       Impact factor: 2.660

4.  Autophagy in Myelinating Glia.

Authors:  Jillian Belgrad; Raffaella De Pace; R Douglas Fields
Journal:  J Neurosci       Date:  2019-11-19       Impact factor: 6.167

Review 5.  Clinical and Molecular Spectrum of Muscular Dystrophies (MDs) with Intellectual Disability (ID): a Comprehensive Overview.

Authors:  Malihe Mohamadian; Mandana Rastegar; Negin Pasamanesh; Ata Ghadiri; Pegah Ghandil; Mohsen Naseri
Journal:  J Mol Neurosci       Date:  2021-11-02       Impact factor: 3.444

6.  Whole-genome sequencing of two probands with hereditary spastic paraplegia reveals novel splice-donor region variant and known pathogenic variant in SPG11.

Authors:  Allen Chi-Shing Yu; Anne Yin-Yan Chan; Wing Chi Au; Yun Shen; Ting Fung Chan; Ho-Yin Edwin Chan
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

7.  SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia.

Authors:  C Paisan-Ruiz; O Dogu; A Yilmaz; H Houlden; A Singleton
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

8.  Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11).

Authors:  C Paisan-Ruiz; P Nath; N W Wood; A Singleton; H Houlden
Journal:  Eur J Neurol       Date:  2008-08-20       Impact factor: 6.089

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.